RenovoRx, Inc.
RNXT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $48 | $31 | $29 |
| - Cash | $10 | $12 | $15 | $7 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $36 | $17 | $22 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -37% | 114.2% | 358.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.1% | 64% | 52.3% | 100% |
| EBITDA | -$3 | -$3 | -$2 | $0 |
| % Margin | -1,094.4% | -634.4% | -1,227.9% | 0% |
| Net Income | -$3 | -$3 | -$2 | -$3 |
| % Margin | -1,094.7% | -686% | -1,228.4% | -6,693% |
| EPS Diluted | -0.08 | -0.079 | -0.077 | -0.13 |
| % Growth | -1% | -2.7% | 40.7% | – |
| Operating Cash Flow | -$2 | -$2 | -$3 | -$2 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$2 | -$3 | -$2 |